Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH – Get Free Report) (TSE:AUP) have been given an average recommendation of “Moderate Buy” by the six analysts that are presently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a hold recommendation, two have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $17.33.
A number of research analysts have recently commented on the company. Royal Bank Of Canada increased their price target on Aurinia Pharmaceuticals from $16.00 to $18.00 and gave the company a “sector perform” rating in a research note on Monday, November 2nd. TD Cowen raised their price objective on Aurinia Pharmaceuticals from $17.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, October 21st. Wall Street Zen lowered Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, November 7th. Weiss Ratings cut Aurinia Pharmaceuticals from a “buy (b)” rating to a “buy (b-)” rating in a report on Wednesday, November 4th. Finally, Bloom Burton raised Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 20th.
Check Out Our Latest Analysis on Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Price Performance
AUPH stock opened at $14.89 on Tuesday. The company has a quick ratio of 5.67, a current ratio of 6.12 and a debt-to-equity ratio of 0.06. Aurinia Pharmaceuticals has a 12 month low of $13.52 and a 12 month high of $19.25. The firm has a market cap of $2.00 billion, a P/E ratio of 14.83 and a beta of 1.40. The company’s 50-day moving average price is $16.41 and its two-hundred day moving average price is $15.73.
Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Free Report) (TSE:AUP) last issued its earnings results on Friday, October 30th. The biotechnology company reported $0.23 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.01. The firm had revenue of $83.70 million for the quarter, compared to the consensus estimate of $83.61 million. Aurinia Pharmaceuticals had a return on equity of 22.99% and a net margin of 97.68%. On average, analysts anticipate that Aurinia Pharmaceuticals will post 0.97 earnings per share for the current fiscal year.
Institutional Trading of Aurinia Pharmaceuticals
Several hedge funds and other institutional investors have recently made changes to their positions in AUPH. BlackRock Inc. bought a new position in Aurinia Pharmaceuticals during the 2nd quarter worth $139,037,000. Goldman Sachs Group Inc. grew its position in shares of Aurinia Pharmaceuticals by 12.8% in the 3rd quarter. Goldman Sachs Group Inc. now owns 6,338,866 shares of the biotechnology company’s stock valued at $102,658,000 after buying an additional 719,465 shares during the last quarter. Renaissance Technologies LLC grew its position in shares of Aurinia Pharmaceuticals by 4.6% in the 1st quarter. Renaissance Technologies LLC now owns 1,663,835 shares of the biotechnology company’s stock valued at $24,658,000 after buying an additional 73,700 shares during the last quarter. Allianz Asset Management GmbH bought a new stake in shares of Aurinia Pharmaceuticals in the 2nd quarter valued at about $14,284,000. Finally, Janus Henderson Group PLC grew its position in shares of Aurinia Pharmaceuticals by 9.7% in the 1st quarter. Janus Henderson Group PLC now owns 757,435 shares of the biotechnology company’s stock valued at $11,225,000 after buying an additional 66,806 shares during the last quarter. 36.83% of the stock is currently owned by institutional investors.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing treatments for autoimmune diseases. The Canadian company’s work has centered on therapies for conditions that can affect the kidneys and other organs. Its lead product, Lupkynis (voclosporin), is an oral medicine approved in the United States to treat adults with active lupus nephritis, a kidney complication of systemic lupus erythematosus. It is used in combination with background immunosuppressive therapy. Aurinia, formerly known as Isotechnika, developed voclosporin as a treatment for lupus nephritis.
Featured Stories
- Five stocks we like better than Aurinia Pharmaceuticals
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
